NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.06% | -3.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.09% | 19.52% | |||
| Operating Income | -56.09% | -19.52% | |||
| Income Before Tax | 739.00% | 93.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 739.00% | 93.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 739.00% | 93.67% | |||
| EBIT | -56.09% | -19.52% | |||
| EBITDA | -56.20% | -19.56% | |||
| EPS Basic | 651.63% | 94.17% | |||
| Normalized Basic EPS | 650.00% | 94.15% | |||
| EPS Diluted | -38.68% | 74.60% | |||
| Normalized Diluted EPS | 593.62% | 94.27% | |||
| Average Basic Shares Outstanding | 15.70% | 8.69% | |||
| Average Diluted Shares Outstanding | 29.98% | 10.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||